Plasma leptin in treated patients with schizophrenia

Haupt, Dan; Schweiger, Julia; Melson, Angela K.; Charepoo, M.; Fahnestock, Peter A; Newcomer, John W.

doi:10.1016/s0920-9964(03)80165-2

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors have also noted that SLL in patients correlated significantly with WG and showed a trend for an association with BMI gains. Haupt and colleagues have pointed out no evidence of modulation of plasma leptin concentration by typical or atypical antipsychotics (olanzapine, risperidone) in 72 schizophrenic patients [ 67 ].…”

Section: Treatment With Other Atypical and Typical Antipsychoticsmentioning

confidence: 99%

The Role of Leptin in Antipsychotic-Induced Weight Gain: Genetic and Non-Genetic Factors

et al. 2012

View full text Add to dashboard Cite

Schizophrenia is a chronic and disabling mental illness affecting millions of people worldwide. A greater proportion of people with schizophrenia tends to be overweight. Antipsychotic medications have been considered the primary risk factor for obesity in schizophrenia, although the mechanisms by which they increase weight and produce metabolic disturbances are unclear. Several lines of research indicate that leptin could be a good candidate involved in pathways linking antipsychotic treatment and weight gain. Leptin is a circulating hormone released by adipocytes in response to increased fat deposition to regulate body weight, acting through receptors in the hypothalamus. In this work, we reviewed preclinical, clinical, and genetic data in order to infer the potential role played by leptin in antipsychotic-induced weight gain considering two main hypotheses: (1) leptin is an epiphenomenon of weight gain; (2) leptin is a consequence of antipsychotic-induced “leptin-resistance status,” causing weight gain.

show abstract

Section: Treatment With Other Atypical and Typical Antipsychoticsmentioning

confidence: 99%